PMID- 29200185
OWN - NLM
STAT- MEDLINE
DCOM- 20190404
LR  - 20190404
IS  - 1532-0987 (Electronic)
IS  - 0891-3668 (Linking)
VI  - 37
IP  - 6
DP  - 2018 Jun
TI  - Early Vaccine-type Pneumococcal Acute Otitis Media Does not Predispose to
      Subsequent Otitis When Compared With Early Acute Otitis Media Due to Other
      Bacterial Etiology.
PG  - 592-594
LID - 10.1097/INF.0000000000001851 [doi]
AB  - BACKGROUND: Prevention of acute otitis media (AOM), and especially recurrence and
      biofilm formation, by pneumococcal conjugate vaccines has been hypothesized to be
      due to prevention of early episodes triggering the vicious cycle. We tested the
      specific role of vaccine-type pneumococcal AOM in this hypothesis. METHODS: In
      the phase III randomized, double-blind Finnish otitis media Vaccine Trial
      conducted in 1995-1999, children received pneumococcal conjugate vaccine 7 or
      hepatitis B vaccine as control at 2, 4, 6, and 12 months of age and were followed
      for AOM. Myringotomy with middle ear fluid aspiration was performed in AOM, and
      samples were cultured. We compared control-vaccinated children with confirmed
      vaccine-type or 6A-AOM with those with AOM due to other confirmed etiology within
      2-6 months of age (early AOM) and followed for subsequent AOM from 6-24 months of
      age. RESULTS: Eight hundred thirty-one children were enrolled in the Finnish
      otitis media control arm. Before 6 months of age, 34 children experienced
      vaccine-type-AOM, and 40 children experienced AOM of other bacterial etiology.
      The subsequent AOM incidences were 1.9 (95% CI, 1.5-2.4) and 2.1 (1.7-2.5) in
      these subgroups, respectively. However, the subsequent incidences were lower if
      no bacteria were detected at AOM (1.5, 1.2-1.8) or if there was no early AOM
      (1.1, 1.1-1.2). CONCLUSIONS: Early vaccine-type AOM was not associated with a
      higher risk of subsequent AOM compared with AOM due to other confirmed bacterial 
      etiology. These data do not support any specific role of vaccine-type
      pneumococcus in the hypothesis.
FAU - Palmu, Arto A
AU  - Palmu AA
AD  - From the Department of Public Health Solutions, National Institute for Health and
      Welfare, Tampere, Finland.
FAU - Lahdenkari, Mika
AU  - Lahdenkari M
AD  - Department of Public Health Solutions, National Institute for Health and Welfare,
      Helsinki, Finland.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pediatr Infect Dis J
JT  - The Pediatric infectious disease journal
JID - 8701858
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Pneumococcal Vaccines)
RN  - 0 (Vaccines, Conjugate)
SB  - IM
CIN - Pediatr Infect Dis J. 2018 Dec;37(12):e351-e352. PMID: 30408013
CIN - Pediatr Infect Dis J. 2018 Dec;37(12):e352-e353. PMID: 30408014
MH  - Child, Preschool
MH  - Disease Susceptibility
MH  - Double-Blind Method
MH  - Female
MH  - Finland
MH  - Hepatitis B Vaccines/therapeutic use
MH  - Humans
MH  - Infant
MH  - Male
MH  - Nasopharynx/microbiology
MH  - Otitis Media/*etiology/*microbiology/prevention & control
MH  - Pneumococcal Infections/*etiology/prevention & control
MH  - Pneumococcal Vaccines/adverse effects/*therapeutic use
MH  - Streptococcus pneumoniae
MH  - Vaccines, Conjugate/administration & dosage/therapeutic use
EDAT- 2017/12/05 06:00
MHDA- 2019/04/05 06:00
CRDT- 2017/12/05 06:00
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2019/04/05 06:00 [medline]
PHST- 2017/12/05 06:00 [entrez]
AID - 10.1097/INF.0000000000001851 [doi]
PST - ppublish
SO  - Pediatr Infect Dis J. 2018 Jun;37(6):592-594. doi: 10.1097/INF.0000000000001851.